Oncology and Hematology

97-112 of 226

• 

  MinuteCE®

  Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  

  Luis Paz-Ares, MD, PhD; Lauren A. Byers, MD

  0.50 credits 6 episodes

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Lauren A. Byers, MD

  0.50 credits 6 episodes

• 

  RestartResume

  Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 

  RestartResume

  Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 

  MinuteCE®

  Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 

  Lauren A. Byers, MD

  0.50 program credits

  • 

    

    Lauren A. Byers, MD

  0.50 program credits

• 

  RestartResume

  Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC

  RestartResume

  Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC

  MinuteCE®

  Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC

  Luis Paz-Ares, MD, PhD

  0.50 program credits

  • 

    

    Luis Paz-Ares, MD, PhD

  0.50 program credits

• 

  RestartResume

  Safety First: Navigating CELMoD-Associated Toxicities

  RestartResume

  Safety First: Navigating CELMoD-Associated Toxicities

  MinuteCE®

  Safety First: Navigating CELMoD-Associated Toxicities

  Joshua Richter, MD; Noopur Raje, MD

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  MinuteCE®

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  Joshua Richter, MD; Noopur Raje, MD

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  MinuteCE®

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  Joshua Richter, MD; Sagar Lonial, MD, FACP

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Why CELMoDs Matter in Myeloma

  RestartResume

  Why CELMoDs Matter in Myeloma

  MinuteCE®

  Why CELMoDs Matter in Myeloma

  Sagar Lonial, MD, FACP

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Mastering the Sequence: CELMoDs Across Treatment Lines

  RestartResume

  Mastering the Sequence: CELMoDs Across Treatment Lines

  MinuteCE®

  Mastering the Sequence: CELMoDs Across Treatment Lines

  Sagar Lonial, MD, FACP; Noopur Raje, MD

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  MinuteCE®

   Real-World Ready: Practical Tips for Community Oncologists

  Joshua Richter, MD; Sagar Lonial, MD, FACP

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  MinuteCE®

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  Noopur Raje, MD

  1.00 program credit

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Data Dive: Clinical Evidence Behind CELMoDs

  RestartResume

  Data Dive: Clinical Evidence Behind CELMoDs

  MinuteCE®

  Data Dive: Clinical Evidence Behind CELMoDs

  Sagar Lonial, MD, FACP

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  MinuteCE®

  Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity

  Joshua Richter, MD; Sagar Lonial, MD, FACP

  1.00 credit 10 episodes

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Noopur Raje, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  RestartResume

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  CME/CE

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  Heather Wakelee, MD, FASCO

  0.25 credits

  • 

    

    Heather Wakelee, MD, FASCO

  0.25 credits

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  John M. Kirkwood, MD; Sapna Patel, MD

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  MinuteCE®

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  MinuteCE®

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  John M. Kirkwood, MD; Sapna Patel, MD

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• Previous
• 1
• 2
• …
• 5
• 6
• 7
• 8
• 9
• …
• 14
• 15
• Next